Literature DB >> 22902411

Transition from colitis to cancer: high Wnt activity sustains the tumor-initiating potential of colon cancer stem cell precursors.

Anitha K Shenoy1, Robert C Fisher, Elizabeth A Butterworth, Liya Pi, Lung-Ji Chang, Henry D Appelman, Myron Chang, Edward W Scott, Emina H Huang.   

Abstract

Ulcerative colitis (UC) increases the risk of colorectal cancer (CRC), but the mechanisms involved in colitis-to-cancer transition (CCT) are not well understood. CCT may involve a inflammation-dysplasia-carcinoma progression sequence compared with the better characterized adenoma-carcinoma progression sequence associated with sporadic CRC. One common thread may be activating mutations in components of the Wnt/β-catenin signaling pathway, which occur commonly as early events in sporadic CRC. To examine this hypothesis, we evaluated possible associations between Wnt/β-catenin signaling and CCT based on the cancer stem cell (CSC) model. Wnt/β-catenin immunostaining indicated that UC patients have a level of Wnt-pathway-active cells that is intermediate between normal colon and CRC. These UC cells exhibiting activation of the Wnt pathway constituted a major subpopulation (52% + 7.21) of the colonic epithelial cells positive for aldehyde dehydrogenase (ALDH), a putative marker of precursor colon CSC (pCCSC). We further fractionated this subpopulation of pCCSC using a Wnt pathway reporter assay. Over successive passages, pCCSCs with the highest Wnt activity exhibited higher clonogenic and tumorigenic potential than pCCSCs with the lowest Wnt activity, thereby establishing the key role of Wnt activity in driving CSC-like properties in these cells. Notably, 5/20 single cell injections of high-Wnt pCCSC resulted in tumor formation, suggesting a correlation with CCT. Attenuation of Wnt/β-catenin in high-Wnt pCCSC by shRNA-mediated downregulation or pharmacological inhibition significantly reduced tumor growth rates. Overall, the results of our study indicates (i) that early activation of Wnt/β-catenin signaling is critical for CCT and (ii) that high levels of Wnt/β-catenin signaling can further demarcate high-ALDH tumor-initiating cells in the nondysplastic epithelium of UC patients. As such, our findings offer plausible diagnostic markers and therapeutic target in the Wnt signaling pathway for early intervention in CCT. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902411      PMCID: PMC3463774          DOI: 10.1158/0008-5472.CAN-12-1806

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

2.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

Review 3.  Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

Authors:  Bryan D White; Andy J Chien; David W Dawson
Journal:  Gastroenterology       Date:  2011-12-08       Impact factor: 22.682

Review 4.  Chronic inflammation and cancer.

Authors:  Emily Shacter; Sigmund A Weitzman
Journal:  Oncology (Williston Park)       Date:  2002-02       Impact factor: 2.990

Review 5.  The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer.

Authors:  Lopa Mishra; Kirti Shetty; Yi Tang; August Stuart; Stephen W Byers
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

6.  Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human: a study of histopathology, B-catenin and p53 expression and the role of inflammation.

Authors:  H S Cooper; S Murthy; K Kido; H Yoshitake; A Flanigan
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis.

Authors:  Emina H Huang; Mark J Hynes; Tao Zhang; Christophe Ginestier; Gabriela Dontu; Henry Appelman; Jeremy Z Fields; Max S Wicha; Bruce M Boman
Journal:  Cancer Res       Date:  2009-03-31       Impact factor: 12.701

9.  Phenotypic characterization of human colorectal cancer stem cells.

Authors:  Piero Dalerba; Scott J Dylla; In-Kyung Park; Rui Liu; Xinhao Wang; Robert W Cho; Timothy Hoey; Austin Gurney; Emina H Huang; Diane M Simeone; Andrew A Shelton; Giorgio Parmiani; Chiara Castelli; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

10.  WNT-pathway activation in IBD-associated colorectal carcinogenesis: potential biomarkers for colonic surveillance.

Authors:  Marian M H Claessen; Marguerite E I Schipper; Bas Oldenburg; Peter D Siersema; G Johan A Offerhaus; Frank P Vleggaar
Journal:  Cell Oncol       Date:  2010-01-01       Impact factor: 6.730

View more
  46 in total

Review 1.  Developing Cures: Targeting Ontogenesis in Cancer.

Authors:  Victor T G Lin; Hawley C Pruitt; Rajeev S Samant; Lalita A Shevde
Journal:  Trends Cancer       Date:  2017-01-27

Review 2.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

Review 3.  Multiple oncogenic roles of nuclear beta-catenin.

Authors:  Raju Kumar; Murali D Bashyam
Journal:  J Biosci       Date:  2017-12       Impact factor: 1.826

4.  Drug-eluting microarrays to identify effective chemotherapeutic combinations targeting patient-derived cancer stem cells.

Authors:  Matthew R Carstens; Robert C Fisher; Abhinav P Acharya; Elizabeth A Butterworth; Edward Scott; Emina H Huang; Benjamin G Keselowsky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

5.  Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin.

Authors:  Shakir M Saud; Matthew R Young; Yava L Jones-Hall; Lilia Ileva; Moses O Evbuomwan; Jennifer Wise; Nancy H Colburn; Young S Kim; Gerd Bobe
Journal:  Cancer Res       Date:  2013-07-01       Impact factor: 12.701

Review 6.  Clonal evolution of colorectal cancer in IBD.

Authors:  Chang-Ho R Choi; Ibrahim Al Bakir; Ailsa L Hart; Trevor A Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-02-08       Impact factor: 46.802

Review 7.  Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances.

Authors:  José Luis Llorente; Fernando López; Carlos Suárez; Mario A Hermsen
Journal:  Nat Rev Clin Oncol       Date:  2014-06-17       Impact factor: 66.675

8.  Diallyl Disulfide (DADS), a Constituent of Garlic, Inactivates NF-κB and Prevents Colitis-Induced Colorectal Cancer by Inhibiting GSK-3β.

Authors:  Shakir M Saud; Weidong Li; Zane Gray; Matthias S Matter; Nancy H Colburn; Matthew R Young; Young S Kim
Journal:  Cancer Prev Res (Phila)       Date:  2016-05-02

9.  HIV infection accelerates gastrointestinal tumor outgrowth in NSG-HuPBL mice.

Authors:  Rong Lu; Shaoping Wu; Yongguo Zhang; Yinglin Xia; Erica J Huelsmann; Andrew T Lacek; Arman Nabatiyan; Maureen H Richards; Srinivas D Narasipura; Victoria Lutgen; Honglei Chen; Howard L Kaufman; Di Chen; Lena Al-Harthi; Andrew Zloza; Jun Sun
Journal:  AIDS Res Hum Retroviruses       Date:  2014-04-03       Impact factor: 2.205

10.  Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes.

Authors:  Belinda Schludi; Abu Saleh Md Moin; Chiara Montemurro; Tatyana Gurlo; Aleksey V Matveyenko; David Kirakossian; David W Dawson; Sarah M Dry; Peter C Butler; Alexandra E Butler
Journal:  JCI Insight       Date:  2017-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.